EP0015615B1 - Phenyl piperazine derivatives, their preparation and antiagressive medicines containing them - Google Patents

Phenyl piperazine derivatives, their preparation and antiagressive medicines containing them Download PDF

Info

Publication number
EP0015615B1
EP0015615B1 EP80200173A EP80200173A EP0015615B1 EP 0015615 B1 EP0015615 B1 EP 0015615B1 EP 80200173 A EP80200173 A EP 80200173A EP 80200173 A EP80200173 A EP 80200173A EP 0015615 B1 EP0015615 B1 EP 0015615B1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
piperazine
stated
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP80200173A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0015615A1 (en
Inventor
Hans Heinz Haeck
Feddo Cornelius Hillen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Priority to AT80200173T priority Critical patent/ATE2219T1/de
Publication of EP0015615A1 publication Critical patent/EP0015615A1/en
Application granted granted Critical
Publication of EP0015615B1 publication Critical patent/EP0015615B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • the invention relates to new phenyl piperazine derivatives, to the preparation of these compounds, and to compositions containing at least one of these compounds as an active substance.
  • United States Patent Specification 2,722,529 relates to compounds of formula 1 of the formula sheet, in which Y is a straight or branched alkyl group having 2-6 carbon atoms and Z is an acyl group, a sulphonyl group or a carbamoyl group. These compounds are said to have a strong sympatholytic activity and sometimes a hypotensive effect.
  • United States Patent Specification 2,833,770 discloses a group of compounds of the general formula 2 of the formula sheet, in which formula R is a chlorine atom or a bromine atom, R' is a hydrogen atom or a methyl group and n is an integer of 2-5. Of these compounds also a sympatholytic effect is known.
  • phenyl piperazine derivatives of formula 3 of the formula sheet in which R 1 is a hydrogen atom, a methyl group, an alkoxy group having 1 or 2 carbon atoms, an amino group or a ureido group, R 2_ is a hydrogen atom or an alkyl group having 1-3 carbon atoms, R 3- a halogen atom or trifluoromethyl group, T is an oxygen or sulfur atom, and n is 0 or 1, and the salts thereof, have a strong antiagressive activity.
  • R 2 represents an alkyl group, this preferably is the methyl group or ethyl group.
  • R 3 is halogen this preferably is fluorine, chlorine or bromine.
  • this antiagessive activity of the compounds according to the invention is not associated with the sympatholytic properties described for the above-mentioned known and structurally closely related compounds, which properties are undesired for antiagressiveness.
  • the Ed SO -values mentioned in the table were determined in a test on antiagressive activity in isolated mice (Advances in Pharmacol. 5, (1967), 79). In this test, male albino mice were kept isolated for a period of 4 weeks and then selected for the test on the basis of fighting behaviour present. The selection criteron is the occurrence of 3 or more fighting periods within 3 minutes after a mouse which has not been kept isolated has been placed in the cage of the mouse kept isolated.
  • the compounds to be investigated were administered orally to the selected mice. Per dose 5 mice were used. Sixty minutes after the administration of the compound to be investigated the animals were evaluated again for fighting behaviour. The compound to be investigated is inactive in the administered dose when now also 3 or more fighting periods were observed within 3 minutes after the mouse not kept isolated was placed in the cage of the mouse kept isolated. The ED 50 -value in mg of active substance per kg of body weight was calculated from the results obtained.
  • the new compounds are excellently suitable -due to their surprisingly selective antiagressive activity pattern- for being used in the treatment of agressive behaviour in man and animal.
  • the quantity, frequency, and way of administration may differ for each individual case, also dependent on the nature and severity of the disturbances.
  • a dosage of from 5-500 mg and preferably from 25-150 mg daily, depending on the way of administration, will generally be suitable.
  • the dosage is preferably 0.1-10 mg/kg of body weight, depending on the way of administration.
  • the active compounds according to the invention and their salts can be processed according to known standard methods to compositions such a pills, tablets, coated tablets, capsules, powders and injection liquids while using the usual auxiliary substances such as solid and liquid carrier materials.
  • acids with which the compounds according to the invention can form salts may be mentioned hydrochloric acid, sulphuric acid, nitric acid, citric acid, fumaric acid, maleic acid, tartaric acid, methane sulphonic acid and benzoic acid.
  • the compounds of formula 3 and their salts can be prepared by methods suitable for the synthesis of analogous compounds.
  • the invention therefore also relates to the preparation of the new compounds and the salts thereof.
  • the reaction with an ester is preferably carried out with an excess of the ester, so that the ester also serves as a solvent, at a temperature between room temperature and the boiling point of the ester used.
  • the reaction with the amide is preferably carried out without a solvent at elevated temperature (see J. Pharm. Soc. Japan, 62 (1942), 531).
  • the reaction with an alkali metal cyanate is preferably carried out in water to which an equivalent amount of an acid, for example, hydrochloric acid or acetic acid, has been added.
  • the reaction mixture is usually stirred at room temperature for a few hours.
  • the reaction with urea is preferably carried out at a temperature of 130-150°C without a solvent.
  • R 1 , R 2 and R 3 have the above meanings and X is a so-called leaving group, preferably chlorine, bromine or tosylate.
  • the reaction may be carried out both with and without an inert organic solvent. Suitable solvents are, for example, methyl ethyl ketone, dimethyl formamide, tetrahydrofuran and petroleum ether.
  • an acid-binding agent is preferably used triethyl amine or potassium carbonate.
  • the reaction temperature is usually between room temperature and 60°C and the reaction duration varies from a few hours to approximately 20 hours.
  • This reaction is usually carried out in a solvent such as benzene, DMSO or dimethyl formamide in the presence of a strong base, for example, KOH or NaOH under anhydrous conditions at temperatures between room temperature and reflux temperature of the solvent (see J. Org. Chem. 14 (1949), 1099).
  • a strong base for example, KOH or NaOH
  • compounds of formula 3 in which R 1 is methyl can be prepared by reaction of a compound of formula 8 with a compound of formula 9, in which formulae R 2' R 3 and X have the above meanings and R 1 is methyl.
  • compounds of formula 3 can be prepared by hydrogenation of a compound of formula 10 with hydrogen and a suitable catalyst (for example platinum oxide or Raney nickel in the presence of a base such as sodium acetate or sodium hydroxide) in acetic acid anhydride and, if desired, in the presence of acetic acid.
  • a suitable catalyst for example platinum oxide or Raney nickel in the presence of a base such as sodium acetate or sodium hydroxide
  • the reaction is preferably carried out at elevated temperature and pressure, for example at 50°C and 3.5 x 10 5 Pa. hydrogen pressure (see J. Org. Chem. 25, (1960), 1658-1660).
  • This reaction is carried out in a solvent for example DMSO, in the presence of an acid-binding agent, for example Na 2 CO 3 .
  • the reaction mixture is stirred at elevated temperature (100 ⁇ 180°C) for a few hours (see DE-A-2.024.826).
  • the compounds of formula 3 can be prepared by converting a compound of formula 13 in which R 1 , R 2 and R 3 have the above meanings, with 1,2-dibromoethane.
  • the reaction is carried out in an organic solvent, for example, dioxan or butanol, in the presence of an acid-binding agent, for example K 2 CO 3 at a temperature of 20 ⁇ 120°C (see Arzneistoff Chemie 27 (11), (1977), 2077-2086).
  • R 3 is chlorine or bromine
  • compounds of formula 3 in which R 3 is chlorine or bromine can also be prepared by diazotization of the corresponding compound in which R 3 is a amino group, with NaNO 2 and HCL or HBr.
  • This reaction step is carried out in an excess of the diluted acid to which another acid, for example sulphuric acid, may be added so as to increase the reactivity, at a temperature of from -10 to +5°C.
  • the resulting reaction mixture is then treated with cuprous chloride or cuprous bromide or with copper at 20-75°C, preferably with the addition of a quantity of concentrated HCI or HBr, respectively, the 3-chloro or the 3-bromo compound, respectively, being formed.
  • the compounds of formula 3 can also be obtained by reacting a compound of formula 14 with a compound of formula 15, in which formulae R 1' R 2 and R 3 have the above meanings. This reaction is preferably carried out in a solvent, for example butanol, in the presence of an acid-binding agent, such as K Z C0 3 , at temperatures between room temperature and the boiling point of the solvent used (see GB-A-943.739).
  • a solvent for example butanol
  • the compounds of formula 3 can be prepared in similar reaction conditions by reaction of a compound of formula 16 with a compound of formula 17, in which formulae R 1 R 2 and R 3 have the above meansings (see Coll. Czech. Chem. Comm. 6 (1934), 211).
  • Compounds of the formula 3 wherein T represents a sulphur atom can also be obtained by reacting a compound of the formula 5 with a compound of the formula R"NCS, wherein R" represents a group which can be easily removed, e.g. an optionally substituted aroyl group. Very suitable for this purpose is the benzoyl group.
  • R"NCS represents a group which can be easily removed, e.g. an optionally substituted aroyl group.
  • the so obtained substituted thiourea derivative can be hydrolised with a base (e.g. 2N NaOH) in a solvent such as ethanol.
  • the reaction with R"NCS is carried out in a solvent such as for example acetone or acetonitrile at temperatures between room temperature and the boiling point of the solvent used.
  • Suitable oxidation agents are hydrogen peroxide, perbenzoic acid, monoperphthalic acid, m-chloroperbenzoic acid, peracetic acid and complexes with hydrogen peroxide. This oxidation reaction can be carried out at temperatures between 0°C and the boiling point of the solvent used.
  • Suitable solvents are inert solvents such as water, mixtures of water and acetone and organic solvents such as alcohols, (e.g. ethanol), ketones (e.g. acetone), acids (e.g. acetic acid), esters (e.g. ethylacetate) and chlorinated hydrocarbons such as CH 2 CI 2 .
  • Example III In the manner described in Example III the title compound (melting point 136-137°C) was obtained from 1-[2-(N-ethylamino)ethyl]-4-(3-trifluoromethylphenyl)piperazine.
  • Example IV the title compound was converted -with methane sulphonic acid- into 1-[2-(N-acetylamino)ethyl]-4-(3-trifluoromethylphenyl)piperazine mesylate with a melting-point of 171.5-173.5°C.
  • Example IV the title compound was converted -with hydrochloric acid- into 1-[2-(N-acetylamino)ethyl]-4-(3-trifluoromethylphenyl)piperazine hydrochloride with a melting point of 197-199°C.
  • Example IV In the manner described in Example IV, a quantity of the title compound was converted -with hydrochloric acid- into 1-[2-(N-acetylamino)ethyl]-4-(3-chlorophenyl)piperazine hydrochloride with a melting-point of 173-175°C.
  • Example IV In the manner described in Example IV, a quantity of the title compound was converted -with methane sulphonic acid- into 1-[2-(N-acetylamina)ethyl]-4-(3-chlaraphenyl)piperazine mesylate with a melting point of 171-173°C.
  • Example IV a quantity of the title compound was converted -with sulphuric acid- into 1-[2-(N-acetylamino)ethyl]-4-(3-chlorophenyl)piperazine sulphate (1:1) with a melting point of 121.5-124°C.
  • Example X the title compound (melting point 85-87°C) was obtained from 1-(3-trifluaramethylphenyl)piperazine.
  • a quantity of the title compound thus obtained was converted in the manner described in Example IV into 1-[2-(N-acetylamino)ethyl]-4-(3-trifluoromethylphenyl)piperazine sulphate (1:1) with a melting point of 119.5-121.5°C.
  • Example X the free base of the title compound was obtained as a resin from 1-(3-trifluoromethylphenyl)piperazine and N-acetyl-N-methyl-2-chloroethylamine.
  • Example IV In the manner described in Example IV, a quantity of the free base was converted -with hydrochloric acid- into the title compound with a melting point of 182-184°C.
  • Example IV a quantity of the free base was converted -with methane sulphonic acid- into 1-[2-(N-acetyl-N-methylamino)ethyl]-4-(3-trifluoromethylphenyl)piperazine mesylate (1:1) with a melting point of 123-124°C.
  • Example IV a quantity of the free base was converted -with maleic acid- into 1-[2-(N-acetyl-N-methylamino)ethyl]-4-(3-trifluoromethylphenyl)piperazine maleate (1:1) with a melting point of 123-124°C.
  • Example X In the manner described in Example X, the title compound (melting point 97.5-99°C) was obtained from 1-(3-fluorophenyl)piperazine.
  • Example X In the manner described in Example X, the title compound (melting point 97-98.5°C) was obtained from 1-(3-bromophenyl)piperazine.
  • Example X the title compound (melting point 186-191 °C) was obtained from 1-(3-chlorophenyl)piperazine and N-acetyl-N-methyl-2-chloroethylamine.
  • the catalyst was removed by filtration and acetic acid anhydride was evaporated under reduced pressure.
  • the residue was purified chromatographically over silica gel with methylene chloride/methanol (95:5) as an eluent. After removing the solvent, the residue was crystallized from toluene/petroleum ether.
  • the title compound obtained in this manner has a melting-point of 85-87°C.
  • the title compound was obtained in an identical manner, using 1-(2-aminoethyl)-4-(3-chlorophenyl)piperazine as the, starting compound.
  • the so obtained title compound had a melting point of 163-164°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Cookers (AREA)
EP80200173A 1979-03-01 1980-02-28 Phenyl piperazine derivatives, their preparation and antiagressive medicines containing them Expired EP0015615B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT80200173T ATE2219T1 (de) 1979-03-01 1980-02-28 Phenyl-piperazin-derivate, ihre herstellung und sie enthaltende anti-agressive heilmittel.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL7901633 1979-03-01
NL7901633 1979-03-01

Publications (2)

Publication Number Publication Date
EP0015615A1 EP0015615A1 (en) 1980-09-17
EP0015615B1 true EP0015615B1 (en) 1983-01-12

Family

ID=19832723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP80200173A Expired EP0015615B1 (en) 1979-03-01 1980-02-28 Phenyl piperazine derivatives, their preparation and antiagressive medicines containing them

Country Status (20)

Country Link
EP (1) EP0015615B1 (el)
JP (1) JPS55141478A (el)
AT (1) ATE2219T1 (el)
AU (1) AU532411B2 (el)
CA (1) CA1138461A (el)
CS (1) CS216525B2 (el)
DD (1) DD151408A5 (el)
DE (1) DE3061561D1 (el)
DK (1) DK84380A (el)
ES (3) ES8106898A1 (el)
FI (1) FI800588A (el)
GR (1) GR67005B (el)
HU (1) HU182070B (el)
IE (1) IE49526B1 (el)
IL (1) IL59489A (el)
PH (1) PH17025A (el)
PL (1) PL126161B1 (el)
SU (1) SU1039442A3 (el)
YU (1) YU54680A (el)
ZA (1) ZA801119B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
NL8005131A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met analgetische werking.
US4457931A (en) * 1982-09-27 1984-07-03 Selvi & C. S.P.A. Piperazine derivatives with anticholinergic and/or antihistaminic activity
JPH0660160B2 (ja) * 1985-12-13 1994-08-10 テルモ株式会社 アミド誘導体およびこれを含有する抗アレルギ−剤
US5340812A (en) * 1989-04-22 1994-08-23 John Wyeth & Brother, Limited Piperazine derivatives
DK0395313T3 (da) * 1989-04-22 2000-06-19 American Home Prod Tertiære alkyl-funktionaliserede piperazin-derivater
US5382583A (en) * 1989-04-22 1995-01-17 John Wyeth & Brother, Limited Piperazine derivatives
FI102175B1 (fi) * 1989-04-22 1998-10-30 Wyeth John & Brother Ltd Menetelmä terapeuttisesti käyttökelpoisten piperatsiinijohdannaisten valmistamiseksi
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
GB9200293D0 (en) * 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833770A (en) * 1958-05-06 Chj-chj
US2722529A (en) * 1955-11-01 Amides of certain l-amevoalkyl-x-phenyl
BE788280A (fr) * 1971-09-04 1973-02-28 Pfizer Nouvelles 1-(3-trifluoro-methyl-phenyl)-4-((amido cyclique)- alkyl) piperazines et composition pharmaceutique les contenant
GB1443598A (en) * 1973-07-06 1976-07-21 Acraf 1- 3-acetylaminopropyl-4-2,5-dichlorophenyl-piperazine
FR2306694A1 (fr) * 1975-04-07 1976-11-05 Parcor Derives de la piperazine

Also Published As

Publication number Publication date
IE49526B1 (en) 1985-10-16
AU532411B2 (en) 1983-09-29
JPS55141478A (en) 1980-11-05
ES488988A0 (es) 1981-09-01
ATE2219T1 (de) 1983-01-15
ES8200883A1 (es) 1981-11-16
SU1039442A3 (ru) 1983-08-30
CS216525B2 (en) 1982-11-26
AU5584880A (en) 1980-09-04
CA1138461A (en) 1982-12-28
IL59489A0 (en) 1980-05-30
PH17025A (en) 1984-05-17
EP0015615A1 (en) 1980-09-17
GR67005B (el) 1981-05-18
FI800588A (fi) 1980-09-02
ES8106898A1 (es) 1981-09-01
ES8200884A1 (es) 1981-11-16
PL222294A1 (el) 1980-12-01
DD151408A5 (de) 1981-10-21
IE800405L (en) 1980-09-01
YU54680A (en) 1983-09-30
ES495105A0 (es) 1981-11-16
DK84380A (da) 1980-09-02
DE3061561D1 (en) 1983-02-17
PL126161B1 (en) 1983-07-30
HU182070B (en) 1983-12-28
ZA801119B (en) 1981-09-30
ES495106A0 (es) 1981-11-16
IL59489A (en) 1984-05-31

Similar Documents

Publication Publication Date Title
EP0254322B1 (en) Benzimidazole derivatives
US4430343A (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
JPS61152666A (ja) 新規な二環式ヘテロアリールピペラジン誘導体、その製造方法およびその誘導体を有効成分とする向精神医薬組成物
EP0048045A1 (en) Phenyl piperazine derivatives having antiagressive activity
WO1997029097A1 (en) Sulfonamide derivatives as 5ht7 receptor antagonists
JPH054391B2 (el)
CA1288102C (en) Pyridine derivatives, their preparation and their use
EP0015615B1 (en) Phenyl piperazine derivatives, their preparation and antiagressive medicines containing them
WO2010128516A2 (en) Process for the preparation of flibanserin involving novel intermediates
PL209573B1 (pl) Benzimidazole i zastosowanie benzimidazoli do wytwarzania środka leczniczego do leczenia lub zapobiegania chorobom związanym z aktywowaniem mikrogleju i środek farmaceutyczny zawierający benzimidazol
HUT73526A (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
US7345075B2 (en) 1,2 diarylbenzimidazoles and their pharmaceutical use
JP2767321B2 (ja) ピペラジン誘導体及びこれを含有する医薬
JPH0794417B2 (ja) Ｎ−アミノブチル−ｎ−フェニルアリールアミド誘導体
EP0255710A2 (en) 1,4-Dihydropyridine derivatives with calcium agonist and alpha-1-antagonist activity
HU176533B (en) Process for preparing o-alkylated hydroxylamines
JP2005536528A (ja) １−メチル−２−（４−アミジノフェニルアミノメチル）−ベンズイミダゾール−５−イル−カルボン酸−（ｎ−２−ピリジル−ｎ−２−ヒドロキシカルボニルエチル）−アミドの新規プロドラッグ、それらの製造及び医薬組成物としてのそれらの使用
US4377576A (en) 5-(Heterocyclic amino-propionyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones
EP0061149B1 (en) Alkylenedioxybenzene derivatives and acid addition salts thereof and a process for their preparation
FR2556720A1 (fr) Derives de l'amidine et tonicardiaques les contenant
JPS596868B2 (ja) 新規イソキノリン誘導体の製造方法
US5486517A (en) Benzimidazoles and imidazopyridines as central nervous system agents
US4086361A (en) Aminoethyl oximes having anti-depressive activity
JPH0692915A (ja) １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
HU187572B (en) Process for preparing 1,5-diphenyl-pyrazolin-3-one derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

17P Request for examination filed

Effective date: 19810304

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

REF Corresponds to:

Ref document number: 2219

Country of ref document: AT

Date of ref document: 19830115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3061561

Country of ref document: DE

Date of ref document: 19830217

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840130

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19840131

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840214

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19840215

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19840229

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840331

Year of fee payment: 5

Ref country code: BE

Payment date: 19840331

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19840418

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19850228

Ref country code: BE

Effective date: 19850228

Ref country code: AT

Effective date: 19850228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19850301

BERE Be: lapsed

Owner name: DUPHAR INTERNATIONAL RESEARCH B.V.

Effective date: 19850228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19850901

GBPC Gb: european patent ceased through non-payment of renewal fee
NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19851031

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19851101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881118

EUG Se: european patent has lapsed

Ref document number: 80200173.5

Effective date: 19860128

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT